FDA Grants De Novo Classification to TytoCare’s AI Otoscopy Tool

The AI-driven software analyzes otoscopy videos to detect eardrum bulging, establishing a new regulatory category for ENT diagnostic aids. TytoCare has received FDA De Novo classification for its Tyto Insights for ENT Suite, an artificial intelligence-powered solution for analyzing otoscopy videos....

Clinicians should note this regulatory milestone as the first FDA-cleared AI otoscopy video analysis tool for eardrum bulging detection, but evidence of clinical accuracy and workflow impact in audiology settings is not yet established from this announcement alone.

This FDA De Novo classification establishes a new regulatory pathway for AI-driven ENT diagnostics, potentially accelerating the adoption of remote or AI-assisted otoscopy in hearing and primary care settings.

1. 01FDA granted De Novo classification to TytoCare's Tyto Insights for ENT Suite.
2. 02The AI tool analyzes otoscopy videos to detect eardrum (tympanic membrane) bulging.
3. 03De Novo classification creates a novel regulatory category for AI-driven ENT diagnostic devices.
4. 04This is distinct from a traditional 510(k) clearance and sets a predicate for future similar devices.
5. 05No peer-reviewed clinical validation data were cited in the trade announcement.